Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes

Investigative Ophthalmology and Visual Science

Volumn 40, Issue 3, 1999, Pages 809-813

  Das, Arup ^a,b   McGuire, Paul G ^a   Eriqat, Cheryl ^a   Ober, Richard R ^c   Dejuan Jr , Eugene ^d   Williams, George A ^e   McLamore, Angela ^a   Biswas, Jyoti ^f   Johnson, David W ^g  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b VA Medical Center   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e WILLIAM BEAUMONT HOSPITAL   (United States)

^f MEDICAL RESEARCH FOUNDATION   (India)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METALLOPROTEINASE; UROKINASE;

ADULT; AGED; ARTICLE; CAPILLARY BASEMENT MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; DIABETES MELLITUS; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; ENZYME ACTIVITY; EPIRETINAL MEMBRANE; HUMAN; MOUSE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; RETINA NEOVASCULARIZATION; TARGET CELL;

AGED; COLLAGENASES; DIABETIC RETINOPATHY; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EPIRETINAL MEMBRANE; GELATINASES; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; MIDDLE AGED; MOLECULAR WEIGHT; RETINAL NEOVASCULARIZATION; URINARY PLASMINOGEN ACTIVATOR; VITRECTOMY;

EID: 0032979479     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Frank RN, Das A. Pathogenic mechanisms In diabetic eye diseases. In: Feman SS, ed. Ocular Problems in Diabetes Mellitus. Boston: Blackwell Scientific; 1992:95-133.
2. Engerman RL, Pfaffenbach D, Davis MD. Cell turnover of capillaries. Lab Invest. 1967;17:738-743.
3. Aiello LP. Vascular endothelial growth factor: 20.th. century mechanisms, 21.st. century therapies. Invest Ophthalmol Vis Sci. 1997; 38:1647-1652.
4. Pepper MS, Montesano R. Protcolytic balance and capillary morphogenesis. Cell Diff Dev. 1990;32:319-327.
5. Das A, McLamore A, McGuire PG. Urokinase and matrix metalloproteinase activity is increased in retinas in a mouse model of retinal neovascularization (ARVO Abstract]. Invest Ophthalmol Vis Sci. 1998;39(4):S450. Abstract nr 2063.
6. McGuire PG, Alexander S. Inhibition of urokinase synthesis and cell surface binding alters the motile behavior of embryonic endocardial-derived mesenchymal cells in vitro. Development. 1993; 118:931-939.
7. Kleiner DE, Stetler-Stevenson WG. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem. 1994; 218:325-329.
8. Das A, Frank RN, Zhang, et al. Ultrastructural immunocytochemistry of preretinal membranes in proliferative diabetic retinopathy [ARVO Abstract]. Invest Ophthalmol Vis Sci. 1990;31:130.
9. Pevarali FA, Mandriota SJ, Ciana P, et al. Tumor cells secrete an angiogenic factor that stimulates basic fibroblast growth factor and urokinase expression in vascular endothelial cells. J Cell Physiol. 1994;161:1-14.
10. Brown D, Hamdi M, Bahri S, Kenny MC. Characterization of an endogenous metalloproteinase in human vitreous. Curr Eye Res. 1994;13:639-647.
11. De La Paz MA, Itoh Y, Toth CA, Nagase H. Matrix metalloproteinases and their inhibitors in human vitreous. Invest Ophthahnol Vis Sci. 1998;39:1256-1260.
12. Jackson DW, McGuire PG, Eriqat C, Das A. Both vascular endothelial growth factor (VEGF) and hypoxia increase gelatinase A (MMP-2) activity in vascular endothelial cells in vitro [ARVO Abstract]. Invest Ophthalmol Vis Sci. 1997;38(4):S500. Abstract nr 2305.
13. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990;6:121-125.
14. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Gabrisa S. Effect of plasminogen activator (urokinase), plasmin and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981:41:4629-4636.
15. McGuire PG, Seeds NW. Degradation of underlying extracellular matrix by sensory neurons during the proces of neurite outgrowth. Neuron. 1990;4:633-642.
16. He C, Wilhem SM, Pentland AP, et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA. 1989;86:2632-2636.
17. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of VEGF using a VEGF-receptor chimeric protein. Proc Natl Acad Sci USA. 1995;92:10457-10461.
18. Robinson GS, Pierce Ea, Rook SL, et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA. 1996;93:4851-4856.
19. Adamis AP, Shima DT, Tolentino MJ. Inhibition of VEGF prevents ocular neovascularization in a non-human primate. Arch Ophthalmol. 1996;93:4851-4856.
20. Smith LEH, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science. 1997;276:1706-1709.
21. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCβ inhibition with LY333531. Invest Ophthalmol Vis Sci. 1998;39: 171-179.
22. McLamore A, Das A, McGuire PG. Inhibition of matrix metalloproteinases suppresses retinal neovascularization [ARVO Abstract]. Invest Ophthalmol Vis Sci. 1998;39(4):S450. Abstract nr 2064.
23. Gallardy RE, Grobelny D, Foellmer HG, Fernandez LA. Inhibition of angiogenesis by the metalloproteinase inhibitor N-2R-2-hydroxamidocarbonymethyl-4-methylpentanoyl-L-tryptophan methylamide. Cancer Res 1994;54:4715-4718.